STOCK TITAN

TELESIS BIO INC - TBIO STOCK NEWS

Welcome to our dedicated page for TELESIS BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TELESIS BIO stock.

Telesis Bio, Inc. (NASDAQ: TBIO) is a leading synthetic biology company revolutionizing the field with its advanced technology for building high-quality synthetic DNA and mRNA. Based in San Diego, Telesis Bio manufactures and distributes a variety of laboratory equipment including synthetic biology instruments, reagents, and related services that empower researchers in various scientific domains.

The company's flagship product, the BioXp® system, is an award-winning, fully automated genomics workstation that streamlines the entire synthesis, cloning, and amplification workflow. This system consolidates various processes, enabling the creation of double-stranded DNA fragments, automated cloning, and next-generation sequencing DNA library preparation. The BioXp system is complemented by BioXp kits, Benchtop reagents, and BioXp biofoundry services, all designed to accelerate synthetic biology workflows.

Telesis Bio is known for its industry-standard Gibson Assembly® method, an essential tool for assembling DNA molecules. The company recently launched the groundbreaking Gibson SOLA platform, which supports high-throughput drug discovery applications and promises significant advantages over existing solutions. This platform ensures high-fidelity synthesis of synthetic oligonucleotides, genes, and transfection-ready mRNA, allowing researchers to achieve results within unprecedented timelines.

In its recent updates, Telesis Bio announced several milestones, including the introduction of new kits to expand their suite of NGS Library Prep solutions on the BioXp System. The company has shown resilience and adaptability, with revenue for the third quarter of 2023 at $5.6 million, despite a challenging economic environment. Their ongoing efforts in cost-cutting have effectively reduced operating expenses and net losses, laying a strong foundation for future growth.

Telesis Bio's technology is crucial in multiple fields, including precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Researchers worldwide rely on their solutions to accelerate the design-build-test paradigm, pushing the boundaries of synthetic biology to address some of humanity's greatest challenges.

As Telesis Bio continues to innovate and expand, they remain committed to providing researchers with the tools and resources needed to drive scientific discovery and application. For more information, visit www.telesisbio.com.

Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced its participation in two upcoming investor conferences. The CEO, Ronald Renaud, will engage in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:30 a.m. ET, and at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 3:50 p.m. ET. A live webcast of these sessions will be available on the company's website, with replays accessible for 30 days post-event. Translate Bio focuses on mRNA therapeutics, particularly for pulmonary diseases, and collaborates with Sanofi Pasteur on mRNA vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced promising preclinical results for a new mRNA-based therapeutic aimed at treating primary ciliary dyskinesia (PCD) due to DNAI1 mutations. The study showed that the delivery of mRNA to the lungs can enhance DNAI1 expression, potentially restoring mucociliary clearance, a crucial mechanism impaired in PCD. The company plans to further advance this candidate into IND-enabling studies in the second half of 2021, addressing a significant unmet need as no approved therapies currently exist for PCD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Translate Bio (TBIO) continues to progress in developing mRNA therapeutics, reporting a net income of $26.5 million for Q1 2021. Significant advancements include the initiation of a COVID-19 vaccine trial (MRT5500) in partnership with Sanofi Pasteur, with interim results expected in Q3 2021. The company also published promising preclinical results for MRT5500. Additionally, the ongoing Phase 1/2 trial for MRT5005 in cystic fibrosis suggests safety and tolerability. Translate Bio has a strong cash position of $654.8 million, funding operations through 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced on May 3, 2021, the grant of non-qualified stock options for 51,200 shares to six new employees as part of its 2021 Inducement Stock Incentive Plan. The options have an exercise price of $23.03 per share, equal to the stock's closing price on the grant date. They vest over four years, with 25% vesting on May 3, 2022, and the remainder in monthly installments. Translate Bio is focused on developing mRNA therapeutics, particularly for pulmonary diseases like cystic fibrosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced that CEO Ronald Renaud will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. EST. A live webcast will be available on the company’s website, and a replay will be archived for 30 days post-event.

Translate Bio focuses on developing mRNA therapeutics for treating diseases like cystic fibrosis and also collaborates with Sanofi Pasteur on mRNA vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced the grant of 201,800 non-qualified stock options to Brendan Smith, its new CFO, on April 19, 2021. This grant is part of the 2021 Inducement Stock Incentive Plan and aligns with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $19.23 per share, equal to the closing stock price on that date. The options have a 10-year term with a four-year vesting schedule. Translate Bio focuses on developing mRNA therapeutics for various diseases, including a candidate for cystic fibrosis currently in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced key leadership appointments on April 19, 2021, aimed at advancing its strategic plan, TBIO 2025. Brendan Smith was appointed Chief Financial Officer, bringing over 20 years of experience in biopharma. Greg Troiano became Chief Manufacturing Officer, enhancing the company's manufacturing capabilities, while Jim Sullivan was named Senior Vice President for Pulmonary Discovery, focusing on mRNA therapeutics for pulmonary diseases. The appointments align with the company's goal of enhancing its R&D investments and advancing multiple drug programs into clinical stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) published preclinical results for its COVID-19 vaccine candidate MRT5500, demonstrating strong immune responses and protective efficacy against SARS-CoV-2 in studies involving multiple species. The vaccine, developed with Sanofi Pasteur, showed that MRT5500 induces neutralizing antibodies and protection against infection in hamster models. A Phase 1/2 clinical trial started in March 2021, with results expected in Q3 2021. The findings support the potential of MRT5500 as an effective vaccination option against COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
Rhea-AI Summary

Translate Bio (NASDAQ: TBIO) announced the granting of non-qualified stock options for 111,800 shares to 14 newly hired employees as part of its 2021 Inducement Stock Incentive Plan. The options have an exercise price of $16.82, equal to the stock's closing price on April 5, 2021. These options vest over four years, with 25% vesting on April 5, 2022. This initiative aims to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4). Translate Bio focuses on developing mRNA therapeutics to treat pulmonary diseases and collaborate on mRNA vaccines for infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Translate Bio (Nasdaq: TBIO) announced the granting of non-qualified stock options for 300,000 shares to its new President, Dr. Rand Sutherland, on March 22, 2021. The exercise price is set at $16.37 per share, corresponding to the closing price on that date. The options have a ten-year term, vesting over four years with specific conditions for early vesting. This grant is part of the company's 2021 Inducement Stock Incentive Plan and aims to incentivize Dr. Sutherland's employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of TELESIS BIO (TBIO)?

The current stock price of TELESIS BIO (TBIO) is $0.38 as of December 24, 2024.

What is the market cap of TELESIS BIO (TBIO)?

The market cap of TELESIS BIO (TBIO) is approximately 5.9M.

What is Telesis Bio, Inc. known for?

Telesis Bio is renowned for its advanced synthetic biology technology, including the award-winning BioXp® system and the industry-standard Gibson Assembly® method.

What are the main products offered by Telesis Bio?

Telesis Bio offers synthetic biology instruments, reagents, and related services. Key products include the BioXp® system, BioXp kits, Benchtop reagents, and BioXp biofoundry services.

How does the BioXp® system benefit researchers?

The BioXp® system automates the synthesis, cloning, and amplification workflows, enabling rapid creation of double-stranded DNA fragments and other processes, significantly speeding up research timelines.

What recent achievements has Telesis Bio announced?

Telesis Bio has launched new NGS Library Prep kits, strengthened its board and management team, and reported resilience in financial performance despite industry challenges.

What is the Gibson SOLA platform?

The Gibson SOLA platform is a high-throughput drug discovery solution that provides high-fidelity synthesis of synthetic oligonucleotides, genes, and transfection-ready mRNA, enabling rapid and reliable research outcomes.

Where is Telesis Bio located?

Telesis Bio is based in San Diego, California.

How has Telesis Bio performed financially recently?

In the third quarter of 2023, Telesis Bio reported $5.6 million in revenue, with ongoing cost-cutting efforts reducing operating expenses and net losses.

What industries benefit from Telesis Bio's technology?

Telesis Bio's technology is used in precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy.

How can I learn more about Telesis Bio's offerings?

For detailed information about Telesis Bio's products and services, visit their official website at www.telesisbio.com.

What are Telesis Bio's future plans?

Telesis Bio intends to focus on expanding the adoption of the Gibson SOLA platform, enhancing the BioXp system's capabilities, and driving growth in mRNA synthesis solutions.

TELESIS BIO INC

Nasdaq:TBIO

TBIO Rankings

TBIO Stock Data

5.89M
69.98M
30.67%
33.17%
1.68%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO